α-硫辛酸治疗创伤性脑损伤的作用:通路与前景
本文为综述,从PubMed、Embase、Scopus、Web of Science和Google Scholar收集关于α-硫辛酸(ALA)治疗创伤性脑损伤(TBI)的临床、体内和体外原始研究。ALA因兼具亲水和疏水特性可穿过血脑屏障直接作用于脑区,作为线粒体酶辅因子参与氧化羧化并补充谷胱甘肽,改善细胞应激时谷胱甘肽/谷胱甘肽二硫化物比值,减少细胞死亡;还通过调控caspase 3、caspase 9、NF-κB及肿瘤坏死因子、诱导型一氧化氮合酶等炎症蛋白调节氧化、炎症和凋亡通路。作者结论认为ALA可能作为TBI患者的治疗选择,但需更多研究和试验调整最佳剂量。
要点
- ALA因兼具亲水和疏水特性可穿过血脑屏障,直接作用于脑区。
- ALA作为线粒体酶辅因子参与氧化羧化,并补充谷胱甘肽等抗氧化剂。
- ALA改善细胞应激时谷胱甘肽/谷胱甘肽二硫化物比值,减少细胞死亡。
- ALA通过调控caspase 3、caspase 9、NF-κB及肿瘤坏死因子、诱导型一氧化氮合酶等调节氧化、炎症和凋亡通路。
- 作者结论认为ALA可能作为TBI治疗选择,但需更多研究和试验调整最佳剂量。
适用人群与场景
- 创伤性脑损伤(TBI)患者,包括原发损伤及其并发症和继发损伤阶段。
研究设计与关键结果
- 综述从PubMed、Embase、Scopus、Web of Science和Google Scholar收集英文原始研究,涵盖临床、体内和体外研究。
- ALA因兼具亲水和疏水特性可穿过血脑屏障,直接作用于脑区。
- ALA作为线粒体酶辅因子参与氧化羧化并补充谷胱甘肽,改善细胞应激时谷胱甘肽/谷胱甘肽二硫化物比值,减少细胞死亡。
- ALA通过调控caspase 3、caspase 9、NF-κB及肿瘤坏死因子、诱导型一氧化氮合酶等炎症蛋白调节氧化、炎症和凋亡通路。
- 目前尚无美国食品药品监督管理局(FDA)批准用于TBI药物治疗的药物。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ALA可能作为TBI患者的治疗选择,但需更多研究和试验调整最佳剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury (TBI) is known to be a critical health challenge with a significant number of hospital admissions. In addition to the primary injury and its complications, the secondary phase of the injury also causes numerous health issues. Neuroinflammation, oxidative stress (OS), and neuronal cell death are among the main outcomes of secondary injury. Although so far there are no drugs approved by the Food and Drug Administration for TBI's pharmacological treatment, numerous pharmaceutical compounds have been studied to help patients. Alpha lipoic acid (ALA), as a potent antioxidant agent, has been investigated for a considerable period.
METHODS: Eligible original studies written in English on the effects of ALA in TBI were collected from PubMed, Embase, Scopus, Web of Science, and Google Scholar for clinical, in vivo, and in vitro studies.
RESULTS: ALA is able to enter the blood-brain barrier due to its distinctive combination of hydrophilic and hydrophobic characteristics, enabling it to directly affect brain regions. It acts as a cofactor for enzymes in mitochondria, helping in oxidative carboxylation and replenishing other antioxidants like glutathione. This improves the glutathione/glutathione disulfide ratio during cellular stress, hence reducing cell death. In addition, ALA regulates oxidative, inflammatory, and apoptotic pathways by controlling the activity of caspase 3, caspase 9, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and inflammatory proteins, including tumor necrosis factor and inducible nitric oxide synthase. These methods highlight the potential of ALA in decreasing neuronal damage and OS in brain-related illnesses, including TBI.
CONCLUSIONS: Based on this review, it can be concluded that ALA can potentially be administered as a therapeutic option for patients with TBI. However, more studies and trials are required to adjust the optimum dosing of ALA for the treatment of patients.
参考来源
- Ataei M, Peyrovinasab A, Saleh M, et al. Exploring the Role of Alpha Lipoic Acid in the Treatment of Traumatic Brain Injury: Pathways and Perspectives. Neurocrit Care. 2025. PMID: 41083749. doi:10.1007/s12028-025-02383-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。